FDA approves pralsetinib for lung cancer with RET gene fusions
The Food and Drug Administration granted accelerated approval to pralsetinib for adult patients with metastatic…
Browsing: Lung Cancer
RethiNKing which immune cells are the best weapon against lung cancer
Immune cells called ‘natural killer’ (NK) cells could be a powerful weapon for fighting lung…
‘Social smokers’ face disproportionate risk of death from lung disease and lung cancer
‘Social smokers’ are more than twice as likely to die of lung disease and more…
Cancer’s ongoing evolution
Cancers gain and lose large sections of chromosomes in some of their cells but not…
Researchers identify RNA molecule that helps lung cancer cells evade immune system
Researchers in Spain have identified a non-coding RNA molecule that helps lung cancer cells proliferate…
Lung cancer trial of RET inhibitor selpercatinib achieves durable responses in majority of patients with RET gene fusions
For patients with non-small cell lung cancers (NSCLC) marked by RET gene fusions, the targeted…
FDA grants priority review to trilaciclib for the treatment of small cell lung cancer
It was announced that the U.S. Food and Drug Administration (FDA) has accepted the New…
IASLC WCLC 2020: CheckMate-743 shows that dual immunotherapy, nivolumab plus ipilimumab improves overall survival for patients with previously untreated mesothelioma
The combination of first-line nivolumab and ipilimumab demonstrated an improvement of overall survival for patients…
IASLC WCLC 2020: Addition of sintilimab to pemetrexed and platinum improved progression-free survival in NSCLC
The interim analysis of ORIENT-11, a phase III double-blind randomised trial has shown a nearly…
IASLC WCLC 2020: Phase 3 eXalt3 study shows significantly longer progression-free survival in patients with ALK lung cancer
Patients with non-small cell lung cancer (NSCLC) carrying anaplastic lymphoma kinase (ALK) gene alterations who…